申请人:CHROMA THERAPEUTICS LTD
公开号:WO2010097586A1
公开(公告)日:2010-09-02
Compounds of formula (I), inhibit HDAC activity: wherein A, B and D independently represent =CH- or =N-; W is-CH=CH- Or -CH2CH2-; R1 is a carboxylic acid group (-COOH), or an ester group which is hydrolysable by one or more intracellular carboxylesterase enzymes to a carboxylic acid group; R2 and R3 are selected from the side chains of a natural or non-natural alpha amino acid, provided that neither R2 nor R3 is hydrogen, or R2 and R3, taken together with the carbon to which they are attached, form a 3-6 membered saturated cycloalkyl or heterocyclyl ring; Y is a bond, -C(=O)-, -S(=O)2-, -C(=O)O-, -C(=O)NR'-, -C(=S)-NR', -C(=NH)NR' or -S(=O)2NR - wherein R' is hydrogen or optionally substituted C1-C6 alkyl; L1 is a divalent radical of formula -(Alk1)m(Q)n(Alk2)p- wherein m, n, p, Q, AIk1 and AIk2 are as defined in the claims; X1 represents a bond; -C(=O); or -S(=O)2-; -NR4C(=O)-, -C(=O)NR4-,- NR4C(=O)NR5-, -NR4S(=O)2-, or -S(=O)2NR4- wherein R4 and R5 are independently hydrogen or optionally substituted C1-C6 alkyl; and z is 0 or 1.
式(I)的化合物抑制HDAC活性:其中A、B和D独立地表示=CH-或=N-;W是-CH=CH-或-CH2CH2-;R1是一个羧酸基(-COOH),或者是可通过一个或多个细胞内羧酯酶酶水解为羧酸基的酯基;R2和R3从天然或非天然α-氨基酸的侧链中选择,前提是R2和R3中没有一个是氢,或者R2和R3与它们附着的碳共同形成一个3-6成员饱和环烷基或杂环烷基环;Y是一个键,-C(=O)-,-S(=O)2-,-C(=O)O-,-C(=O)NR'-,-C(=S)-NR',-C(=NH)NR'或-S(=O)2NR-其中R'是氢或可选择地取代的C1-C6烷基;L1是一个具有式-(Alk1)m(Q)n(Alk2)p-的二价基团,其中m、n、p、Q、Alk1和Alk2如索引中所定义;X1代表一个键;-C(=O);或-S(=O)2-;-NR4C(=O)-,-C(=O)NR4-,-NR4C(=O)NR5-,-NR4S(=O)2-或-S(=O)2NR4-其中R4和R5独立地是氢或可选择地取代的C1-C6烷基;z为0或1。